P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847352.16311.ea |
| _version_ | 1797285907742588928 |
|---|---|
| author | E. Joffe G. Nowakowski H. Tun A. Rosenthal M. Lunning R. Ramchandren C.-C. Li L. Zhou E. Martinez R. von Roemeling R. Earhart M. McMahon I. Isufi L. Leslie |
| author_facet | E. Joffe G. Nowakowski H. Tun A. Rosenthal M. Lunning R. Ramchandren C.-C. Li L. Zhou E. Martinez R. von Roemeling R. Earhart M. McMahon I. Isufi L. Leslie |
| author_sort | E. Joffe |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:12Z |
| format | Article |
| id | doaj.art-06334392b0a64cde9f47e9d7e5d5e893 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:12Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-06334392b0a64cde9f47e9d7e5d5e8932024-03-02T07:47:21ZengWileyHemaSphere2572-92412022-06-0161011101210.1097/01.HS9.0000847352.16311.ea202206003-01011P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIESE. Joffe0G. Nowakowski1H. Tun2A. Rosenthal3M. Lunning4R. Ramchandren5C.-C. Li6L. Zhou7E. Martinez8R. von Roemeling9R. Earhart10M. McMahon11I. Isufi12L. Leslie131 MSKCC, NY2 Mayo Clinic-Minnesota, Rochester, Rochester3 Mayo Clinic-Florida, Jacksonville4 Department of Hematology, Mayo Clinic- Arizona, Phoenix5 University of Nebraska, Omaha6 University of Tennessee Medical Center, Knoxville7 Curis, Lexington7 Curis, Lexington7 Curis, Lexington7 Curis, Lexington7 Curis, Lexington7 Curis, Lexington8 Yale New Haven Hospital, New Haven9 John Theurer Cancer Center, Hackensack, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847352.16311.ea |
| spellingShingle | E. Joffe G. Nowakowski H. Tun A. Rosenthal M. Lunning R. Ramchandren C.-C. Li L. Zhou E. Martinez R. von Roemeling R. Earhart M. McMahon I. Isufi L. Leslie P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES HemaSphere |
| title | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_full | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_fullStr | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_full_unstemmed | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_short | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_sort | p1121 takeaim lymphoma an open label dose escalation and expansion trial of emavusertib ca 4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies |
| url | http://journals.lww.com/10.1097/01.HS9.0000847352.16311.ea |
| work_keys_str_mv | AT ejoffe p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT gnowakowski p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT htun p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT arosenthal p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT mlunning p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT rramchandren p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT ccli p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT lzhou p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT emartinez p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT rvonroemeling p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT rearhart p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT mmcmahon p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT iisufi p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT lleslie p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies |